Loss of histone methyltransferase KMT2D (also known as MLL4) in lung cancer results in a global reduction in SE acetylation levels due to inhibition of H3K4 methylation at promoters, including at the transcription factor PER2 which negatively regulates glycolytic genes [18]. Here, KMT2D is linked to lung carcinoma.